Cellics Therapeutics
- Biotech or pharma, therapeutic R&D
Cellics Therapeutics, Inc. is advancing the novel biomimetic nanomedicine platform termed Cellular Nanoparticles (CNP™). While most therapies act on a single target, many undertreated diseases arise from the dysregulation of multiple pathways. CNPs are designed to overcome the shortcomings of existing approaches by targeting the complex biology of hard-to-treat inflammatory, immune-mediated, and infectious diseases. The Company’s pioneering platform was invented by scientific founder Liangfang Zhang, Ph.D., a leader in biomimetic nanomedicine and the Joan and Irwin Jacobs Chancellor Professor and Department Chair of Chemical and Nano Engineering at UC San Diego. The founding Scientific Advisory Board includes Dr. Robert Langer, the David H. Koch Institute Professor at MIT. Dr. Zhang’s groundbreaking work underpins Cellics’ mission to transform the treatment of serious diseases by harnessing the targeted power of cell surface protein and receptor biology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}